2012-09-18 08:10:37 - Recently published research from Global Markets Direct, "Febrile Neutropenia - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Febrile Neutropenia - Pipeline Review, H2 2012', provides an overview of the Febrile Neutropenia therapeutic pipeline. This report provides information on the therapeutic development for Febrile Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Febrile Neutropenia. 'Febrile Neutropenia - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/463802_febrile_neutropenia_pipeline_review_h ..


Note*: Certain sections in the report may be removed or altered based

on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Febrile Neutropenia.
* A review of the Febrile Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Febrile Neutropenia pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Febrile Neutropenia.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Febrile Neutropenia pipeline depth and focus of Febrile Neutropenia therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Febrile Neutropenia Therapeutic Products under Development, Key Players in Febrile Neutropenia Therapeutics, Febrile Neutropenia Pipeline Overview, Febrile Neutropenia Pipeline, Febrile Neutropenia Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Febrile Neutropenia Overview
Therapeutics Development
An Overview of Pipeline Products for Febrile Neutropenia
Febrile Neutropenia Therapeutics under Development by Companies
Febrile Neutropenia Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Febrile Neutropenia Therapeutics - Products under Development by Companies
Febrile Neutropenia Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Febrile Neutropenia Therapeutics Development
Kyowa Hakko Kirin Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Febrile Neutropenia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
KRN125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRN125 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YP-18 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AQB-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cefepime - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Meropenem - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mycamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Febrile Neutropenia Therapeutics - Drug Profile Updates
Febrile Neutropenia Therapeutics - Discontinued Products
Febrile Neutropenia Therapeutics - Dormant Products
Febrile Neutropenia - Product Development Milestones
Featured News & Press Releases
May 30, 2012: Aequus Presents Proof Of Concept Data Of GlycoPolymer Technology At International Symposium For Polymer Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Febrile Neutropenia, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463802&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.